D-Index & Metrics Best Publications

Evangelos Terpos

National and Kapodistrian University of Athens
Greece

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 90 Citations 35,605 934 World Ranking 7554 National Ranking 17

Overview

What is he best known for?

The fields of study Evangelos Terpos is best known for:

Cancer
Gene
Chemotherapy

The research on Bortezomib, Lenalidomide and Thalidomide is part of his Multiple myeloma project. He performs multidisciplinary study in Internal medicine and Pathology in his work. Pathology and Internal medicine are two areas of study in which he engages in interdisciplinary research. He connects Surgery with Oncology in his research. In his works, Evangelos Terpos undertakes multidisciplinary study on Osteoporosis and Bone disease. Evangelos Terpos undertakes multidisciplinary studies into Immunology and Antibody in his work. Evangelos Terpos combines Antibody and Immunology in his studies. He integrates several fields in his works, including Biochemistry and Enzyme. He conducted interdisciplinary study in his works that combined Enzyme and Biochemistry.

His most cited work include:

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma (2848 citations)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma (1554 citations)
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders (780 citations)

What are the main themes of his work throughout his whole career to date

Internal medicine is intertwined with Oncology, Surgery, Gastroenterology, Pathology and Endocrinology in his research. In his papers, he integrates diverse fields, such as Pathology and Internal medicine. His Multiple myeloma study combines Bortezomib and Lenalidomide studies. In his works, Evangelos Terpos undertakes multidisciplinary study on Immunology and Antibody. He connects Antibody with Immunology in his study. He conducts interdisciplinary study in the fields of Osteoporosis and Bone disease through his works. In his research, he undertakes multidisciplinary study on Bone disease and Osteoporosis. He combines Bone marrow and Multiple myeloma in his research.

Evangelos Terpos most often published in these fields:

Internal medicine (89.50%)
Multiple myeloma (64.61%)
Oncology (39.95%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade.
Lancet Oncology (2014)

3617 Citations

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie.
Lancet Oncology (2016)

1673 Citations

Hematological findings and complications of COVID-19.

Evangelos Terpos;Ioannis Ntanasis-Stathopoulos;Ismail Elalamy;Efstathios Kastritis.
American Journal of Hematology (2020)

1380 Citations

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

Amy V. Jones;Sebastian Kreil;Katerina Zoi;Katherine Waghorn.
Blood (2005)

1115 Citations

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P. Moreau;J. San Miguel;P. Sonneveld;M. V. Mateos.
Annals of Oncology (2010)

679 Citations

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

Antonio Palumbo;Sara Bringhen;Maria Victoria Mateos;Alessandra Larocca.
Blood (2015)

610 Citations

Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid

M. A. Dimopoulos;E. Kastritis;C. Bamia;I. Melakopoulos.
Annals of Oncology (2009)

504 Citations

Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group

Meletios A. Dimopoulos;Evangelos Terpos;Asher Chanan-Khan;Nelson Leung.
Journal of Clinical Oncology (2010)

482 Citations

Soluble receptor activator of nuclear factor κB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index

Evangelos Terpos;Richard Szydlo;Richard Szydlo;Jane F. Apperley;Jane F. Apperley;Evdoxia Hatjiharissi;Evdoxia Hatjiharissi.
Blood (2003)

477 Citations

Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid

Meletios A Dimopoulos;Efstathios Kastritis;Athanasios Anagnostopoulos;Ioannis Melakopoulos.
Haematologica (2006)

441 Citations

If you think any of the details on this page are incorrect, let us know.